Solid Biosciences (SLDB) Non-Current Assets (2017 - 2026)

Solid Biosciences has reported Non-Current Assets for 10 years, with the latest figure at $26.1 million in Q1 2026.

• Quarterly Non-Current Assets fell 14.4% year-over-year to $26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.1 million (down 14.4% YoY) and the FY2025 annual result came in at $27.1 million, down 13.64% from the prior year.
• Non-Current Assets declined to $26.1 million in Q1 2026 per SLDB's latest filing, from $27.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $40.6 million in Q4 2022 and troughed at $8.9 million in Q1 2022.
• A 5-year average of $32.1 million and a median of $33.4 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets slipped 18.54% in 2022, then jumped 335.67% in 2023.
• Over 5 years, Non-Current Assets stood at $40.6 million in 2022, then declined by 13.32% to $35.2 million in 2023, then dropped by 10.92% to $31.4 million in 2024, then slipped by 13.64% to $27.1 million in 2025, then fell by 3.61% to $26.1 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $26.1 million, $27.1 million, and $29.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.